OR WAIT null SECS
August 31, 2016
Last week CPhI Worldwide announced the trends to be covered during its CPhI Pre-Connect Congress on Oct. 3, 2016.
The morning session will be dedicated to drug design and delivery, during which panel discussions will analyze special drug designation with small patient populations-looking at orphan drugs, breakthrough therapies, and highly potent APIs (HPAPIs) across discovery, development, and commercialization. Sessions on cutting edge innovations, model based technologies, and patient-centric design of combination products will complement the agenda.
The congress will also discuss how the changing dynamic of global API manufacturing is forcing manufacturers to innovate and seek new approaches in formulation, sourcing, and manufacturing. Key trends include the tightening of GMP regulations, higher costs through user fees, more stringent requirements for API suppliers in Europe, and the changes continuous processing is bringing.
With a large number of biologics and biosimilars being developed, the biologics track will focus on innovative products and technologies addressing complex disease profiles. The congress will look at the global biosimilars sector including America, Europe, and other emerging markets. Particular emphasis will be placed on the development of Zarxio, the interchangeability of biosimilars, single-use technologies, personalized medicines, and ADCs.
A session will focus on serialization and pharma packaging, including presentations on improving patient care through tamper verification systems, the future of the serialization process, and accessible packaging-focusing on children and elderly patients. The track will also feature regulatory updates on Europe’s Falsified Medicines Directive, and patient adherence and compliance in pharma packaging.